Do-Coop Drug Delivery Systems, Drug Development for the Pharma Industry
Neowater, Water Based Nanotechnology- 2010 Frost & Sullivan Nanotech Technology Alert
Click on the following link to view the Frost & Sullivan article about Do-Coop novel Nanote...
 
October 12, 2009: Interview with Eran Gabbai, Do-Coop CEO and Ayelet Dilion-Mashiah, VP BD & CFO -Overcoming obstacles in drug development
Interview with Eran Gabbai, Do-Coop CEO and Ayelet Dilion-Mashiah, VP BD & CFO (Page 54/55)...
 
October 12, 2009: An article by Eran Gabbai, Do-Coop CEO on the latest issue of Next Generation Pharmaceutical brochure
A link to the article on the NGP website: Neowater: Not Science Fiction, Just Good Science  ...
 
August 09, 2009: An article by Ayelet Dilion-Mashiah Do-Coop VP business development and CFO on the latest Next Generation Pharmaceutical brochure
Like a bridge over troubled waters: Neowater closes R&D gaps for the pharma and biotech industry...
 
July 15, 2009: Champions Biotechnology Partners with Do-Coop Technologies Ltd. to Advance its Novel Oncology Compound SG410, Champions first agent in drug development pipline Into Biomerk Tumorgraft Testing
 ...
 
26th January- 27st January 2010: Do-coop Technologies Ltd. will participate in the World Drug Delivery and Formulation 2010
Do-Coop technologies will participate this year at the World Drug Delivery and Formulation 2010&nb...
 

April 23, 2008: New publication shead more light on the water science of Neowater®

  The paper entitl...
 

February 14, 2008: Is Hybridoma Production About to Take a Quantum Leap Forward?

  Recently published research* h...
 

Do-Coop - Drug Development, Drug Delivery Systems for the Pharma Industry

Neowater®, a novel proprietary water-based nanotechnology, is a commercially available broad enabling platform upon which research, diagnostics, biotech and pharma companies can obtain disruptive price-performance results and overcome current technology barriers with a graceful implementation.

This technology has significant value-added in injectable, oral, topical, ophthalmic, inhaled, transdermal and transmucosal
drug delivery applications due to increased stability and bioavailability of hydrophilic and hydrophobic compounds hydrated with Neowater® and without or with less organic solvents. Drug development can be enhanced and expedited in an efficient way when utilizing Neowater® in the process of compound hydration.

From a biopharma point of view, Neowater® can enhance protein stabilization and among other, enzyme stabilization. Utilizing stem cells media (or standard cells media) based on Neowater® can enhance stem cells growth, cell line growth, stem cell cryopreservation and cell line cryopreservation. Stem cell viability as well as cell line viability can also be enhanced using Neowater®-based media. 

See our main fields of interest below:

CORE TECHNOLOGY: What is Neowater® and how it is created? What are the challenges Neowater® introduce to Modern Physics?
PHARMA : Pharma Opportunities, solutions for the Pharma industry, Small molecule solubilization                                                                 BIOPHARMA: Learn how Neowater® can improve your life/product
DIAGNOSTICS: Fast and efficient detection of diseases through the use of Neowater®-based reagents 

NEWS & EVENTS Stay tuned - check out our latest news and upcoming events Do-Coop will participate in                                                              ADVISORY BOARD: Do-Coop Technologies Scientific advisory board is composed of leading scientists in the fields of Physics and Biology
CONTACT US: Find out more on how we can help you.